Who is the CEO of CMG Pharmaceutical?

According to the DART company overview, CMG Pharmaceutical's representative director is 이주형 (name as registered in Korean). The company was founded on 2001-08-01.

Where is CMG Pharmaceutical listed?

CMG Pharmaceutical trades on the Korea Exchange KOSDAQ market under the ticker 058820. Its fiscal year ends in December.

Does CMG Pharmaceutical pay a dividend?

CMG Pharmaceutical did not pay a cash dividend for fiscal 2025, according to its annual report.

Does CMG Pharmaceutical have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Insider selling (officers or major shareholders reported cutting shares (30 days)). These are factual flags, not investment advice.

Which companies are in the same industry as CMG Pharmaceutical?

Under the Korean Standard Industrial Classification recorded on DART, CMG Pharmaceutical is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

CMG Pharmaceutical KRX:058820KOSDAQ

CMG제약 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h2

Articles, 7 days4

DART filings, 7 days1

Articles tracked24since Sep 11

In Q2 2026, CMG Pharmaceutical reported revenue of ₩28.3bn, up 24.7% year on year, and an operating loss of ₩3.0bn. CMG Pharmaceutical (CMG제약) appeared in 4 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 21 with 17 articles. The most common catalyst was tech & capacity (16).

Filing signals Insider selling Screener

CMG Pharmaceutical quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩28.3bn	+24.7%	−₩3.0bn margin −10.4%	₩2.1bn
Q1 2026	₩25.5bn	+23.7%	−₩2.9bn margin −11.5%	₩113m
Q4 2025 derived	₩31.5bn	+18.0%	₩1.0bn margin 3.3%	−₩3.3bn
Q3 2025	₩30.4bn	+23.0%	₩1.2bn margin 4.0%	₩5.7bn
Q2 2025	₩22.7bn	-8.8%	−₩4.6bn margin −20.3%	−₩10.9bn
Q1 2025	₩20.6bn	-9.6%	−₩1.3bn margin −6.5%	−₩1.6bn
Q4 2024 derived	₩26.7bn	+21.5%	₩460m margin 1.7%	−₩2.8bn
Q3 2024	₩24.7bn	+5.0%	₩134m margin 0.5%	−₩2.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

CMG Pharmaceutical top stories 2 weeks, by number of outlets

1
CMG제약- SKY동물메디컬센터 반려동물 건강관리 영양제 공동개발
11 outlets · 11 articlesFirst report Oct 21 09:28 더바이오Partnership
2
CMG제약, SKY동물메디컬센터와 맞손…반려동물 헬스케어 사업 확대
2 outlets · 2 articlesFirst report Oct 21 13:20 EBN
3
[공시] CMG제약 주권매매거래정지해제 (액면병합 주권 변경상장)
1 outlets · 1 articlesFirst report Oct 26 15:58 스페셜타임스Negative news
4
CMG제약, SKY동물메디컬센터와 반려동물 영양제 공동개발 MOU 체결
1 outlets · 1 articlesFirst report Oct 21 15:32 전자신문Partnership
5
CMG제약·인천스카이동물메디컬센터, 엑소좀 활용 반려동물 영양제 공동개발
1 outlets · 1 articlesFirst report Oct 29 16:29 데일리벳Partnership
6
CMG제약, 동물병원과 손잡고 반려동물 영양제 개발
1 outlets · 1 articlesFirst report Oct 21 15:35 아주경제Partnership

Latest CMG Pharmaceutical news Korean headlines

06:08

CMG제약, 소수계좌 매도 집중에 30일 투자주의
비건뉴스
Oct 2916:29

MajorCMG제약·인천스카이동물메디컬센터, 엑소좀 활용 반려동물 영양제 공동개발
데일리벳Partnership
Oct 2709:03

FeaturedCMG제약, 액면병합 후 거래 재개 첫날 하락세
이투데이
Oct 2615:58

Major[공시] CMG제약 주권매매거래정지해제 (액면병합 주권 변경상장)
스페셜타임스Negative news
Oct 2205:00

"반려동물 건강관리" CMG제약, 스카이동물메디컬센터와 공동개발 협약
파이낸셜포스트Partnership
Oct 2115:35

CMG제약, 동물병원과 손잡고 반려동물 영양제 개발
아주경제Partnership
Oct 2115:32

MajorCMG제약, SKY동물메디컬센터와 반려동물 영양제 공동개발 MOU 체결
전자신문Partnership
Oct 2114:55

CMG제약, SKY동물메디컬센터와 반려동물 건강관리 제품 개발 나선다
한국경제
Oct 2113:20
CMG제약, SKY동물메디컬센터와 맞손…반려동물 헬스케어 사업 확대
EBN
1 more on this story · 1 outlets
- CMG제약, 동물병원과 손잡고 반려동물 헬스케어 사업 확대포인트데일리 · Oct 21 16:19
Oct 2111:00

CMG제약, 펫 헬스케어 판 키운다…동물병원과 맞손
한스경제
Oct 2109:28
MajorCMG제약- SKY동물메디컬센터 반려동물 건강관리 영양제 공동개발
더바이오Partnership
10 more on this story · 10 outlets
- CMG제약, SKY동물메디컬센터와 반려동물 영양제 공동개발바이오타임즈 · Oct 21 09:28
- CMG제약·SKY동물메디컬센터, 반려동물 영양제 공동개발메디파나뉴스 · Oct 21 09:34
- CMG제약, SKY동물메디컬센터와 반려동물 영양제 공동개발뉴스핌 · Oct 21 09:50
- CMG제약-SKY동물메디컬센터, '반려동물 영양제' 공동개발뉴데일리경제 · Oct 21 13:48
- CMG제약, SKY동물메디컬센터와 반려동물 영양제 공동개발FETV · Oct 21 14:37
- CMG제약, SKY동물메디컬센터와 반려동물 건강관리 제품 공동개발뉴스1 · Oct 21 14:50
- CMG제약, SKY동물메디컬센터와 반려동물 영양제 공동개발서울경제 · Oct 21 14:56
- CMG제약·SKY동물메디컬센터, 엑소좀 기반 반려동물 영양제 공동개발헤럴드경제 · Oct 21 15:03
- "반려동물 건강관리"…CMG제약, 공동개발 협약뉴시스경제 · Oct 21 15:13
- CMG제약, SKY동물메디컬센터와 반려동물 건강관리 제품 공동개발파이낸셜뉴스 · Oct 21 15:21
Sep 2816:49

Major[공시] CMG제약 주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)
스페셜타임스Negative news
Sep 1708:24

[화촉] CMG제약 이주형 대표이사 영애 화촉
메디칼업저버

Articles per day 2 weeks

1721

122

126

127

129

130

Company profile

CEO: 이주형
Industry: Pharmaceuticals
Founded: 2001-08-01
Fiscal year-end: December
Head office: 서울특별시 강남구
Website: cmgpharma.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

차바이오텍24.23%
오라이언자산운용9.20%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	655
Yuhan	₩66.9bn	484
Daewoong Pharma	₩68.1bn	372
GC Biopharma	₩1.7bn	326
DongKookPharmaceutical	₩26.1bn	259
Daewon Pharmaceutical	−₩9m	197
Kwangdong Pharmaceutical	₩2.8bn	188
JW Pharmaceutical	₩33.3bn	185

Compare CMG Pharmaceutical side by side with these companies

CMG Pharmaceutical DART filings

Oct 2615:45

Trading halt / delisting 주권매매거래정지해제 (액면병합 주권 변경상장)
Risk & warnings
Oct 1413:12

5% ownership report 주식등의대량보유상황보고서(약식)
Ownership reports
Oct 1216:34

Other 전환사채(해외전환사채포함)발행후만기전사채취득 (제8회차)
Other
Oct 1216:18

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Oct 1216:13

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Oct 1216:09

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 2816:23

Trading halt / delisting 주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)
Risk & warnings

Catalysts 2 weeks

Tech & capacity16
Risk & warnings1

Mentioned alongside 2 weeks

No co-mentioned companies yet.

CMG Pharmaceutical FAQ

Who is the CEO of CMG Pharmaceutical?: According to the DART company overview, CMG Pharmaceutical's representative director is 이주형 (name as registered in Korean). The company was founded on 2001-08-01.
Where is CMG Pharmaceutical listed?: CMG Pharmaceutical trades on the Korea Exchange KOSDAQ market under the ticker 058820. Its fiscal year ends in December.
What were CMG Pharmaceutical's latest quarterly results?: In Q2 2026, CMG Pharmaceutical reported revenue of ₩28.3bn, up 24.7% year on year, and an operating loss of ₩3.0bn. Figures come from reports filed on DART.
Does CMG Pharmaceutical pay a dividend?: CMG Pharmaceutical did not pay a cash dividend for fiscal 2025, according to its annual report.
Does CMG Pharmaceutical have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Insider selling (officers or major shareholders reported cutting shares (30 days)). These are factual flags, not investment advice.
Which companies are in the same industry as CMG Pharmaceutical?: Under the Korean Standard Industrial Classification recorded on DART, CMG Pharmaceutical is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.